AR015514A1 - AMIDA COMPOUND, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT - Google Patents

AMIDA COMPOUND, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT

Info

Publication number
AR015514A1
AR015514A1 ARP990100525A ARP990100525A AR015514A1 AR 015514 A1 AR015514 A1 AR 015514A1 AR P990100525 A ARP990100525 A AR P990100525A AR P990100525 A ARP990100525 A AR P990100525A AR 015514 A1 AR015514 A1 AR 015514A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
nr7r8
alkoxy
formula
Prior art date
Application number
ARP990100525A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802842.6A external-priority patent/GB9802842D0/en
Priority claimed from GBGB9810688.3A external-priority patent/GB9810688D0/en
Priority claimed from GBGB9826553.1A external-priority patent/GB9826553D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR015514A1 publication Critical patent/AR015514A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

Un compuesto de amida inhibidor de células B que tiene la formula (A). En donde cualquiera de: 1) Z es O; n es 0 o 1; T es un residuo de formula (I), endonde R6 es H; alquilo C1-6 opcionalmente sustituido en la posicion terminal por halogeno, OH, NR7R8, COOH, CO-O-alquilo C1-4, o CO-NR7R8; alquilo C1-6interrumpido por uno o más heteroátomos seleccionados a partir de N, O o S, y sustituido en la posicion terminal por halogeno, OH, NR7R8, COOH, CO-O-alquiloC1-4, o CO-NR7R8; OR9; NHR10; ciano; o formilo; cada uno de R7 y R8 es independientemente H, alquilo C1-4, omega-HO-alquilo C1-4, CHO o heterocicloalquiloC1-4, o R7 y R8 forman junto con el átomo de nitrogeno con el que están enlazados, un anillo heterocíclico; R9 es alquilo C1-6 sustituidoen la posicionterminal por OH o NR7R8; R10 es alquilo C1-6 sustituido en la posicion terminal por OH o NR7R8; y W es un residuo de formula (II) en donde: i) X es -CR1=, endonde R1 es H, F, CF3, alquilo C1-4, o NH2; y R2 es H, F, OH, alcoxi C1-4, CN,NO2, CF3 o NHCO-alquilo C1-4; R3 es H, halogeno, CN, NO2, CF3, NH2 u OH; R4 esH, halogeno, CF3, o alcoxi C1-4; y R5 es H, halogeno, alcoxi C1-4, tioalquilo C1-4, CF3, NH2, alquilo C1-4, o un grupo heterocíclico; o ii) X es -N=; y R3 esH, halogeno, NH2, alcoxi C1-4, OH, -O(CH2)3-NH2, piperidino, o CF3; R4 es H, F, CF3, CN o NO2; y cada uno de R2 y R5 es H; 2) Z es O o S; n es 0 o 1; T es unresiduo de formula (III), en donde: R11 es H, CH3 o C2H5; R12 es H, halogeno, alquilo C1-4, o cicloalquiloC3-6; R13 es H, halogeno, hidroxi, alcoxi C1-2,fenilalcoxi C1-2, o alquilo C1-2 sustituido por NH2, NH(alquilo C1-5), NH-SO2-alquilo C1-2, o NH-CO-alcoxi C1-4; y W es un residuo de formula (IV) en donde:uno de R14, R15 y R16 es F, CF3, OCF3, CN, alquilo C2-4, di-(alquilo C1-2)amino o carbamoílo, y los otros dos símbolos son H; o uno de R14, R15 y R16 es H, ylos otros 2 símbolos son cada uno CF3, cada uno de R14, R15 y R16 es H; o cada uno de R14, R15 y R16 es halogeno; el grupo fenil-amida o tiamida está unido acualquiera de los átomos de C libres del anillo de indol; en el entendido de que, cuando R13 es H, cuando menos uno de R14, R15 y R16 sea diferente de H, enA B cell inhibitor amide compound having the formula (A). Where any of: 1) Z is O; n is 0 or 1; T is a residue of formula (I), where R6 is H; C1-6 alkyl optionally substituted at the terminal position by halogen, OH, NR7R8, COOH, CO-O-C1-4 alkyl, or CO-NR7R8; C1-6 alkyl interrupted by one or more heteroatoms selected from N, O or S, and substituted in the terminal position by halogen, OH, NR7R8, COOH, CO-O-C1-4alkyl, or CO-NR7R8; OR9; NHR10; cyano; or formyl; each of R7 and R8 is independently H, C1-4 alkyl, omega-HO-C1-4 alkyl, CHO or C1-4 heterocycloalkyl, or R7 and R8 form together with the nitrogen atom to which they are linked, a heterocyclic ring ; R9 is C1-6 alkyl substituted at the terminal position by OH or NR7R8; R10 is C1-6 alkyl substituted at the terminal position by OH or NR7R8; and W is a residue of formula (II) wherein: i) X is -CR1 =, where R1 is H, F, CF3, C1-4 alkyl, or NH2; and R2 is H, F, OH, C1-4 alkoxy, CN, NO2, CF3 or NHCO-C1-4 alkyl; R3 is H, halogen, CN, NO2, CF3, NH2 or OH; R4 is H, halogen, CF3, or C1-4 alkoxy; and R5 is H, halogen, C1-4 alkoxy, C1-4 thioalkyl, CF3, NH2, C1-4 alkyl, or a heterocyclic group; or ii) X is -N =; and R3 is H, halogen, NH2, C1-4 alkoxy, OH, -O (CH2) 3-NH2, piperidino, or CF3; R4 is H, F, CF3, CN or NO2; and each of R2 and R5 is H; 2) Z is O or S; n is 0 or 1; T is a residue of formula (III), wherein: R11 is H, CH3 or C2H5; R 12 is H, halogen, C 1-4 alkyl, or C 3-6 cycloalkyl; R13 is H, halogen, hydroxy, C1-2 alkoxy, C1-2 phenylalkoxy, or C1-2 alkyl substituted by NH2, NH (C1-5 alkyl), NH-SO2-C1-2 alkyl, or NH-CO-alkoxy C1-4; and W is a residue of formula (IV) wherein: one of R14, R15 and R16 is F, CF3, OCF3, CN, C2-4 alkyl, di- (C1-2 alkyl) amino or carbamoyl, and the other two symbols are H; or one of R14, R15 and R16 is H, and the other 2 symbols are each CF3, each of R14, R15 and R16 is H; or each of R14, R15 and R16 is halogen; the phenyl-amide or thiamide group is attached to any of the free C atoms of the indole ring; with the understanding that, when R13 is H, at least one of R14, R15 and R16 is different from H, in

ARP990100525A 1998-02-10 1999-02-08 AMIDA COMPOUND, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT AR015514A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802842.6A GB9802842D0 (en) 1998-02-10 1998-02-10 Organic compounds
GBGB9810688.3A GB9810688D0 (en) 1998-05-19 1998-05-19 Organic compounds
GBGB9826553.1A GB9826553D0 (en) 1998-12-02 1998-12-02 Organic compounds

Publications (1)

Publication Number Publication Date
AR015514A1 true AR015514A1 (en) 2001-05-02

Family

ID=27269204

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100525A AR015514A1 (en) 1998-02-10 1999-02-08 AMIDA COMPOUND, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT

Country Status (5)

Country Link
AR (1) AR015514A1 (en)
AU (1) AU2832399A (en)
CO (1) CO4980854A1 (en)
PE (1) PE20000281A1 (en)
WO (1) WO1999041239A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001277731A1 (en) 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
JP2004521878A (en) * 2000-12-07 2004-07-22 スィーヴィー　セラピューティクス　インコーポレイテッド Compounds that increase ABCA-1
US6951848B2 (en) 2001-03-12 2005-10-04 Millennium Pharmaceuticals, Inc., Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
ES2255624T3 (en) 2001-08-15 2006-07-01 E. I. Du Pont De Nemours And Company ARIL AMIDAS REPLACED WITH ORTO-HETEROCICLIC GROUPS FOR THE CONTROL OF INVERTEBRATE PESTS.
WO2003059258A2 (en) 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
WO2012002527A1 (en) * 2010-07-02 2012-01-05 あすか製薬株式会社 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR
EP2672963A4 (en) 2011-02-08 2015-06-24 Childrens Medical Center Methods for treatment of melanoma
EP2847165A2 (en) * 2012-04-02 2015-03-18 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Indole, indoline derivatives, compositions comprising them and uses thereof
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
PL3200786T3 (en) 2014-10-03 2020-03-31 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
US10730839B2 (en) * 2016-11-27 2020-08-04 Russell Dahl Quinolines as cytoprotective agents
CN111164075A (en) * 2017-09-20 2020-05-15 北京加科思新药研发有限公司 Fused ring derivatives useful as FGFR4 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1305458A (en) * 1969-02-26 1973-01-31
US3699123A (en) * 1970-03-24 1972-10-17 Sandoz Ltd 4-(3-amino-2-hydroxy-propoxy) indole derivatives
FR2121394A1 (en) * 1971-01-08 1972-08-25 Anvar 2-methyl indole 3-carboxylic acid amides - antiinflammatories analgesics, tranquillisers, fungicides, herbicides and inters
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands

Also Published As

Publication number Publication date
WO1999041239A1 (en) 1999-08-19
PE20000281A1 (en) 2000-05-15
CO4980854A1 (en) 2000-11-27
AU2832399A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
AR015514A1 (en) AMIDA COMPOUND, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT
AR006720A1 (en) A COMPOUND DERIVED FROM HETERO-CYCLIC AZAHEXANE, ITS USE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, PROCEDURE FOR PREPARING IT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
CO5170518A1 (en) N- (BENZOCICLOALQUILO) COMPOUNDS DERIVED FROM AMINO ARALIFATICOS
AR028531A1 (en) ORGANIC COMPOUNDS
AR046200A1 (en) DERIVATIVES OF PIRAZINA AND ITS PHARMACEUTICAL USE. PHARMACEUTICAL PREPARATION AND COMPOSITION PROCESSES
PE20040780A1 (en) HETEROCICLIC COMPOUNDS AS ANTAGONIST OF CGRP AND PROCEDURE FOR THEIR PREPARATION
AR032621A1 (en) COMPOUNDS DERIVED FROM THIOPHEN, METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE IN THE MANUFACTURE OF MEDICINES
PE20070218A1 (en) AMINO-HYDANTOIN CYCLOALKYL COMPOUNDS AND USE OF THESE FOR THE MODULATION OF ß-SECRETASE
PE20030703A1 (en) 17B-HYDROXIESTEROID DEHYDROGENASE TYPE 3 INHIBITORS
ES2191484T3 (en) HETEROCICLICAL COMPOUNDS AS INHIBITORS OF ROTAMASA ENZYMES.
AR060623A1 (en) COMPOUNDS DERIVED FROM 2-AZETIDINONE AND A PREPARATION METHOD
AR040031A1 (en) PIRAZOL-PYRIMIDINE ANILINE COMPOUNDS USED AS KINASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
KR950321212A (en) 4-amino-1-piperidylbenzoylguanidine
BRPI0511186A (en) compound, compound prodrug, pharmaceutical composition, use of compound, and process for preparing compound
AR031597A1 (en) PIPERIDINE COMPOUNDS, A PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITIONS, AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR USE AS CCR-3 INHIBITORS
AR018159A1 (en) COMPOUNDS DERIVED FROM AMIDIN-AMINO-HALOGENATED ACIDS USED AS INHIBITORS OF OXIDE-NITRICO-SYNTHEASE, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND TREATMENT METHOD
CO5590960A2 (en) DERIVATIVES OF AZAINDOLILALQUILAMINA AS LIGANDOS OF 5- HYDROXITRIPTAMINE-6
DE69725007D1 (en) DELTA 1.6 BICYCLO (4,4,0) BASED DYES FOR CONTRAST ENHANCEMENT IN OPTICAL IMAGE GENERATION
BG103258A (en) Azinyloxy- and phenoxydiaryl derivatives of carboxylic acids, their preparation and application as mixed eta/etb endothelin-receptor antagonists
NO981609L (en) Fused tropane derivatives that inhibit neurotransmitter uptake
PE20011212A1 (en) COMPOUNDS FOR THE TREATMENT OF FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME
SE9703377D0 (en) New compounds
DK0412933T3 (en) Coating Materials
BR9401407A (en) Alkaline earth metal salts, transition metal salts and transition metal complexes, coating composition, use of compounds, processes for protecting a metal substrate and for the preparation of metal and product salts
AR015964A1 (en) ISOQUINOLINE COMPOUNDS, ITS USE, PROCEDURE TO TREAT AN AFFECTION, COMPOUND PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITION THAT LOCONTIATES AND USEFUL COMPOUND IN THIS PROCEDURE